Algeria and the United States of America signed Wednesday in San Diego (California) the memorandum of understanding for the creation of a biotechnological centre in Sidi Abdallah (Algiers) which marks, from now on, the effective launch of this project devoted to biotechnologies and pharmaceutical industries.
This document was signed by Mohamed Mansouri, director of Algerian Pharmaceutical Control Laboratory and by Samir Khalil, executive director for North African and Middle Eastern regions to the Pharmaceutical Research and Manufacturers of America Foundation (PhRMA) in the presence of Algerian ambassador to Washington Abdallah Baali.
Crowning a process initiated in 2011, this agreement was inked on the sidelines of the annual global conference-exhibition “BIO International Convention” which is being held in San Diego (23 to 26 June) with the participation of an Algerian delegation made up of representatives from Health and Higher Education Ministries as well as pharmaceutical companies.
Through this Algerian-American strategic partnership in the field of health, Algeria was chosen to host by 2020, in accordance with the objectives outlined in the report “Algeria Vision 2020,” the centre of excellence in biotechnology for the African and Middle Eastern regions like those of Boston for North America, Singapore for Asia and Ireland for Europe.
The agreement includes the specific commitments of each side as well as a system for the good implementation of the objectives as defined in the report ''Algeria Vision 2020'' aimed at developing a biotechnological centre in Algeria.